DB06450ExperimentalSmall molecule
IP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis. The compound was developed by Indevus Pharmaceuticals.
- Primary indication
- Investigated for use/treatment in liver disease.Curator reviewed
- Code names
- IP501
Which companies are running trials of IP501, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account